- Report
- May 2025
- 196 Pages
Global
From €3131EUR$3,545USD£2,675GBP
€3479EUR$3,939USD£2,972GBP
- Report
- May 2025
- 184 Pages
Global
From €3131EUR$3,545USD£2,675GBP
€3479EUR$3,939USD£2,972GBP
- Report
- April 2025
- 200 Pages
Global
From €3966EUR$4,490USD£3,387GBP
- Report
- June 2025
- 898 Pages
Global
From €5167EUR$5,850USD£4,413GBP
- Report
- April 2025
- 150 Pages
Global
From €2649EUR$2,999USD£2,263GBP
- Report
- March 2025
- 185 Pages
Global
From €3378EUR$3,825USD£2,886GBP
€3974EUR$4,500USD£3,395GBP
- Report
- August 2024
- 164 Pages
Global
From €4412EUR$4,995USD£3,768GBP
- Report
- February 2023
- 198 Pages
Global
From €6624EUR$7,500USD£5,658GBP
Eszopiclone is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is classified as a central nervous system (CNS) drug and is a member of the cyclopyrrolone family. Eszopiclone works by binding to the same receptors as benzodiazepines, but with a different chemical structure. It is believed to have fewer side effects than benzodiazepines, and is generally considered to be safer and more effective. Eszopiclone is available in both generic and brand-name forms, and is typically prescribed for short-term use.
Eszopiclone is used to treat a variety of sleep disorders, including difficulty falling asleep, difficulty staying asleep, and early morning awakenings. It is also used to treat insomnia caused by jet lag or shift work. Eszopiclone is not recommended for long-term use, as it can lead to dependence and tolerance.
Some companies in the Eszopiclone market include Sunovion Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more